Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study

NCT03756103 is registered in ClinicalTrials.gov with Shanghai Pharmaceuticals Holding Co., Ltd as lead sponsor.

NCT NCT03756103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03756103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients: A Randomized, Double-Blinded, Dose-Exploration and Placebo-Controlled Study
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2019
Completion date
June 30, 2020
Enrollment
120 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension,essential